AzTrials
AzTrials

Sedentary BehaviorREMOVENCT04153214

Effects of Cycling Workstation on Cardiometabolic Health for Workers With an Office-sitting Desk (REMOVE)

A study testing cycling in people with Sedentary Behavior, run by University Hospital, Clermont-Ferrand at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The recent literature has highlighting the importance of the time of inactivity and the level of physical activity (PA) as predictors of metabolic cardio risks. Now, sedentary lifestyles are well recognized as one of the causes of mortality. Read more about this study

Who is it for?
Ages 18 to 61 years
Conditions the study is for
Sedentary Behavior
What is being tested?
cycling
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
75 participants
Where
1 siteFrance
Study dates
6 Jan 2020to Jan 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 61 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Healthy volunteer, male or female, between 18 and 61 years old
  • Body mass index > 18,5 kg/m2 and ≤ 35 kg/m2
  • More than 0.8 full time equivalent hours (FTE) with 75% of this time in a sitting position
  • Able to provide informed consent to research participation
  • Registered in the French social security system

Who cannot join

  • Work involving multiple periods of sitting interruptions >1 minute
  • Subject using a sit-to-stand office desk or a swiss ball
  • Sports activity > 2.5 hours/week
  • Contact jobs (face-to-face with people)
  • Pregnant or breastfeeding women
  • Medical or surgical history determined by principal investigator to be not compatible with the study
Show all 22Show fewer
  • Subject with cardiorespiratory and/or osteo-articular disorders limiting their ability to perform physical tests or the use of active offices
  • Subject with type 1 or type 2 diabetes treated with insulin
  • Subject with progressive cardiovascular or neoplastic disease.
  • Subject with a major infection within 3 months of inclusion.
  • Subject with known neuromuscular pathology: myopathy, myasthenia, rhabdomyolysis, paraplegia, hemiplegia
  • Subject with chronic or acute inflammatory pathology 3 months prior to inclusion
  • Subject treated by beta-blocker
  • Subject diagnosed and/or treated for schizophrenia, bipolar disorders, major depression
  • Subject treated, or having stopped treatment for less than 3 months prior to inclusion, by corticosteroids, immunosuppressant, anabolic, growth hormone.
  • Subject with unstable psychiatric condition
  • Significant alcohol consumption (> 2-3 drinks per day depending on gender) or presence of substance abuse.
  • Unable to walk or pedal 45 minutes in a row
  • Subject who is excluded from another study or who received more than €4,500 in the year following his participation in clinical studies
  • Subject deprived of their liberty by judicial or administrative decision
  • Refusal to sign written consent to participate
  • Subject participating in another study

Trial locations and contacts

1 site in 1 country.

France1 site, 1 recruiting
  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63003

    Martine Duclos, 0473751664, mduclos@chu-clermontferrand.fr

    Martine Duclos

    Recruiting

Other trials in France

About this study

Official title: Effects of Cycling Workstation on Cardiometabolic Health for Workers With an Office-sitting Desk

The recent literature has highlighting the importance of the time of inactivity and the level of physical activity (PA) as predictors of metabolic cardio risks. Now, sedentary lifestyles are well recognized as one of the causes of mortality. As with physical activity, a dose-response relationship appears to exist: mortality would increase with time spent in sedentary behaviors. However, this relationship would not be linear: the more the daily sitting time increases, the more the consequences on mortality are important. It is now well demonstrated that time spent in sedentary adult behaviour finds primarily its origin in the work, characterized by prolonged and uninterrupted periods of sitting. Many strategies have been settled to break the prolonged sitting time. The most promising one seem to be the use of active workstations (treadmill, cycling, stepping) because they reduce sedentary time at work and increase physical activity with positive effects on the global health. If active workstations have demonstrated their effectiveness with overweight or obese people by increasing daily energy expenditure, their interest in prevention in normal weight people is less known. In addition, the long-term effectiveness of a program of reactivation by active workstation on biological parameters, quantitative and qualitative time of sedentary behaviour (duration, number of breaks) and physical fitness was not assessed.

The main objective of this project is to study the effects of the use of a cycling workstation for 60 minutes per day (30 minutes twice a day) for 3 months among professionals with an office-sitting desk on overall quantity of physical activity time (work and non-work) and sedentary time.

Read the detailed description

Subject will have a pre-inclusion visit during a medical consultation where the eligibility criteria to participate to this study will be checked.

After the inclusion of subject and their agreements to participate to the study, they will know in which group they are :

  • Group who performs 30minutes twice a working day from day 1 to day 180 (interventional)
  • Group who performs 30minutes twice a working day from day 90 to day 180 (control)

They will have evaluation at three different times : T0 (Day 1), T1 (Day 90), T2 (Day 180). The evaluation will evaluate :

  • overall quantity and quality of physical activity time (work and non-work) and sedentary time
  • Body composition
  • Biological parameters
  • Physical fitness
  • Psychological parameters At the end of the protocol, there will be an assessment of the obstacles or motivations to this program.
Being tested
cycling
Keywords
Cardiometabolic health, Sedentary Behavior, Active workstation, Cycling desk
Medical subject headings
Sedentary Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • cyclingBehavioural

    Participants will have a portable pedal machine under their desk and will use it 60minutes per day

Study groups in NCT04153214
Study groupRoleWhat they receive
Cycling workstationExperimentalParticipants will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 6 months
Receives: Behavioral: cycling
controlPlacebo comparatorDaily activities unchanged during 3 months. Then they will have a portable pedal machine under their desk and will use it 60minutes per day (30minutes in the morning and 30minutes in the afternoon) during 3 months.
Receives: Behavioral: cycling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. effects of the use of a cycling Workstation for 60 minutes per day (30 minutes twice a day) for 3 months among professionals with an office-sitting desk on overall quantity of physical activity time (work and non-work) and sedentary time

    Quantify by the use of an accelerometer device wears at the hip

    Measured: month 3

Secondary outcomes (36)
  1. Body composition

    Body fat mass, body fat free mass will be assessed by bioimpedance analysis

    Measured: day 90

  2. Body composition

    Body fat mass, body fat free mass will be assessed by bioimpedance analysis

    Measured: day 180

  3. Body composition

    Body fat mass, body fat free mass will be assessed by bioimpedance analysis

    Measured: day 1

  4. Biological parameters - insulin

    will be assessed in the fasting state using blood sample (insulin mlUI/L)

    Measured: Day 1

  5. Biological parameters - insulin

    will be assessed in the fasting state using blood sample (insulin mlUI/L)

    Measured: Day 90

  6. Biological parameters - insulin

    will be assessed in the fasting state using blood sample (insulin mlUI/L)

    Measured: Day 180

  7. Biological parameters - glucose

    will be assessed in the fasting state using blood sample (glucose g/L)

    Measured: Day 1

  8. Biological parameters - glucose

    will be assessed in the fasting state using blood sample (glucose g/L)

    Measured: Day 90

  9. Biological parameters - glucose

    will be assessed in the fasting state using blood sample (glucose g/L)

    Measured: Day 180

  10. Biological parameters - triglycerides

    will be assessed in the fasting state using blood sample (triglycerides g/L)

    Measured: Day 1

  11. Biological parameters - triglycerides

    will be assessed in the fasting state using blood sample (triglycerides g/L)

    Measured: Day 90

  12. Biological parameters - triglycerides

    will be assessed in the fasting state using blood sample (triglycerides g/L)

    Measured: Day 180

  13. Biological parameters - cholesterol

    will be assessed in the fasting state using blood sample (cholesterol g/L)

    Measured: Day 1

  14. Biological parameters - cholesterol

    will be assessed in the fasting state using blood sample (cholesterol g/L)

    Measured: Day 90

  15. Biological parameters - cholesterol

    will be assessed in the fasting state using blood sample (cholesterol g/L)

    Measured: Day 180

  16. Biological parameters - CRP

    will be assessed in the fasting state using blood sample (CRP-us mg/L)

    Measured: Day 1

  17. Biological parameters - CRP

    will be assessed in the fasting state using blood sample (CRP-us mg/L)

    Measured: Day 90

  18. Biological parameters - CRP

    will be assessed in the fasting state using blood sample (CRP-us mg/L)

    Measured: Day 180

  19. Biological parameters - anandamide

    will be assessed in the fasting state using blood sample (plasma concentration anandamide pmol/ml)

    Measured: Day 1

  20. Biological parameters - anandamide

    will be assessed in the fasting state using blood sample (plasma concentration anandamide pmol/ml)

    Measured: Day 90

  21. Biological parameters - anandamide

    will be assessed in the fasting state using blood sample (plasma concentration anandamide pmol/ml)

    Measured: Day 180

  22. Psychological assessment

    Through an evaluation of healthy life span, stress at work and outside, stress management and anxiety (questionnaires)

    Measured: Day 1

  23. Psychological assessment

    Through an evaluation of healthy life span, stress at work and outside, stress management and anxiety (questionnaires)

    Measured: Day 90

  24. Psychological assessment

    Through an evaluation of healthy life span, stress at work and outside, stress management and anxiety (questionnaires)

    Measured: Day 180

  25. Resting metabolic rate

    will be assessed at rest during 30 minutes using indirect calorimetry

    Measured: Day 1

  26. Resting metabolic rate

    will be assessed at rest during 30 minutes using indirect calorimetry

    Measured: Day 90

  27. Resting metabolic rate

    will be assessed at rest during 30 minutes using indirect calorimetry

    Measured: Day 180

  28. Physical capacity

    will be assessed with the Step Test 6 minutes

    Measured: Day 1

  29. Physical capacity

    will be assessed with the Step Test 6 minutes

    Measured: Day 90

  30. Physical capacity

    will be assessed with the Step Test 6 minutes

    Measured: Day 180

  31. Muscle Strength

    will be assessed with handgrip for upper limb muscle and isokinetic dynamometer for lower limb muscle

    Measured: Day 1

  32. Muscle Strength

    will be assessed with handgrip for upper limb muscle and isokinetic dynamometer for lower limb muscle

    Measured: Day 90

  33. Muscle Strength

    will be assessed with handgrip for upper limb muscle and isokinetic dynamometer for lower limb muscle

    Measured: Day 180

  34. Quality of the time spend to physical activities and sedentary behaviour

    • moderate and high intensity physical activity
    • low intensity physical activity
    • total sedentary time
    • number of sedentary periods of ≥30 minutes, ≤10 minutes, 10 to 30 minutes Evaluate by the use of an accelerometer device wears at the hip

    Measured: Day 1

  35. Quality of the time spend to physical activities and sedentary behaviour

    • moderate and high intensity physical activity
    • low intensity physical activity
    • total sedentary time
    • number of sedentary periods of ≥30 minutes, ≤10 minutes, 10 to 30 minutes Evaluate by the use of an accelerometer device wears at the hip

    Measured: Day 90

  36. Quality of the time spend to physical activities and sedentary behaviour

    • moderate and high intensity physical activity
    • low intensity physical activity
    • total sedentary time
    • number of sedentary periods of ≥30 minutes, ≤10 minutes, 10 to 30 minutes Evaluate by the use of an accelerometer device wears at the hip

    Measured: Day 180

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Nov 2019
  2. Study start6 Jan 2020
  3. Primary completionJan 2021 (estimated)
  4. Study completionJan 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
75 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04153214
Sponsor's protocol ID
RBHP 2019 DUCLOS 2
Other IDs
2019-A04449-48
Acronym
REMOVE
Status last verified
Jan 2020
First submitted
4 Nov 2019
Last updated
22 Jan 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Nasir H, Dutheil F, Ramos I, Guirado T, de Saint-Vincent S, Thivel D, Metz L, Duclos M. Effects of portable pedal machines at work on lipoprotein subfraction profile in sedentary workers - the REMOVE study. Lipids Health Dis. 2024 Apr 14;23(1):105. doi: 10.1186/s12944-024-02098-w.

    PubMed 38616275
  • Guirado T, Metz L, Pereira B, Brun C, Birat A, Boscaro A, Bergouignan A, Thivel D, Duclos M. A 12-Week Cycling Workstation Intervention Improves Cardiometabolic Risk Factors in Healthy Inactive Office Workers. J Occup Environ Med. 2022 Aug 1;64(8):e467-e474. doi: 10.1097/JOM.0000000000002583. Epub 2022 Jun 11.

    PubMed 35673701
  • Guirado T, Metz L, Pereira B, Bergouignan A, Thivel D, Duclos M. Effects of cycling workstation to get tertiary employee moving on their overall health: study protocol for a REMOVE trial. Trials. 2021 May 22;22(1):359. doi: 10.1186/s13063-021-05317-2.

    PubMed 34022938

Questions about this trial

What is this clinical trial studying?

A study testing cycling in people with Sedentary Behavior, run by University Hospital, Clermont-Ferrand at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Lise LACLAUTRE (04 73 75 11 95, drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

effects of the use of a cycling Workstation for 60 minutes per day (30 minutes twice a day) for 3 months among professionals with an office-sitting desk on overall quantity of physical activity time (work and non-work) and sedentary time (time frame: month 3). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04153214, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in